hat subsequent events and
developments may cause these views, expectations and beliefs to change.
However, while Idenix may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any obligation to do
so.
Idenix Pharmaceuticals' Contact:
Amy Sullivan (617) 995-9838
IDENIX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
Three Months Ended Six Months Ended
June 30, June 30,
2008 2007 2008 2007
Revenues:
Collaboration revenue -
related party $1,433 $18,674 $3,478 $43,025
Other revenue 159 1,058 157 1,513
Total revenues 1,592 19,732 3,635 44,538
Operating expenses (1):
Cost of sales 415 167 810 237
Research and
development 14,136 24,570 29,004 47,124
Selling, general and
administrative 6,651 19,837 14,972 35,677
Restructuring charges 37 ------ 297 ------
Total operating
expenses 21,239 44,574 45,083 83,038
Loss from operations (19,647) (24,842) (41,448) (38,500)
Investment income and
other income, net 485 1,802 1,425 3,780
Loss before income taxes (19,162) (23,040) (40,023) (34,720)
Income tax benefit 256 138 657 249
Net loss $(18,906) $(22,902) $(39,
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference2.
Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference3.
Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference4.
Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)5.
Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results6.
Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference7.
Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results8.
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs9.
Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 3110.
Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP11.
Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule